癌症疫苗市場規模、佔有率和成長分析：按疫苗類型、技術、適應症、最終用戶和地區分類－2026-2033年產業預測

2024 年全球癌症疫苗市場價值 120 億美元，預計到 2025 年將成長至 133.2 億美元，到 2033 年將成長至 307 億美元，在預測期（2026-2033 年）內複合年成長率為 11.0%。

全球癌症疫苗市場已從利基市場轉向醫療保健領域，這主要得益於免疫腫瘤學的進步和對有效疫苗日益成長的需求。癌症疫苗有雙重作用：一是預防致癌性病毒，二是治療性地活化免疫系統，對抗腫瘤特異性抗原。這能夠產生持久的免疫反應，有望降低長期醫療成本。市場正從傳統的預防性疫苗發展到新型自體療法以及前沿的新抗原和mRNA技術。基因測序和可擴展的mRNA生產等技術創新正在降低研發門檻，並吸引私營部門和大型製藥公司投資進行後期臨床試驗。此外，與法規結構的協調一致也為輔助療法、新興市場以及旨在提供個人化疫苗解決方案的策略夥伴關係創造了盈利的機會。

全球癌症疫苗市場促進因素

全球癌症疫苗市場正受到抗原發現、遞送系統和佐劑配方方面進步的顯著推動。這些進步提高了癌症疫苗在各種腫瘤類型中的療效和適用性。這些創新降低了科學上的不確定性，簡化了轉化研究流程，並提升了臨床醫生和研發人員對治療價值的認知。這種環境促進了投資增加、合作研究計畫的發展，以及癌症疫苗研發在研發管線中的優先地位。因此，候選疫苗的研發正在加速，疫苗種類日益豐富，產品線更加完善，相關人員的信心不斷增強，市場也因此成長。

全球癌症疫苗市場面臨的限制因素

應對各地區嚴格的監管要求和不同的核准框架，為癌症疫苗的研發和上市帶來了巨大挑戰。這種多方面的複雜性增加了不確定性，延長了研發週期。為了清楚證明臨床療效、有效調整試驗設計並滿足獨特的安全標準，研發公司需要提供大量的證據，這可能會扼殺小規模的研發公司，並阻礙其產品組合的進展。此外，監管流程的零碎化增加了合規和策略規劃所需的資源，最終減緩了新型候選疫苗的核准進程，並限制了其產品進入市場的速度。

全球癌症疫苗市場趨勢

全球癌症疫苗市場正經歷著向個人化新抗原疫苗的顯著轉變，這反映了精準腫瘤學領域更廣泛的趨勢，即根據每位患者獨特的腫瘤特徵量身定做個人化療法。研發人員越來越注重基於生物標記的患者篩選和診斷，以最佳化治療效果。商業策略也針對特定患者群體進行調整，基於價值的報銷模式正獲得支付方的廣泛支持。此外，生產和供應鏈流程也向敏捷、按需的工作流程演進。同時，監管路徑和臨床試驗設計也日趨完善，以支持這些個人化療法，並越來越重視真實世界數據（REW），以證明其在不同腫瘤類型中的臨床獲益。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球癌症疫苗市場規模：依疫苗類型分類

• 預防性癌症疫苗
• 用於治療的癌症疫苗
• 聯合疫苗

全球癌症疫苗市場規模：依技術分類

• 重組癌症疫苗
• mRNA和新抗原個人化疫苗
• 病毒載體和DNA疫苗
• 全細胞疫苗和樹突細胞疫苗
• 基於胜肽的疫苗
• 抗原/佐劑癌症疫苗

全球癌症疫苗市場規模：依適應症（癌症類型）分類

• 子宮頸癌
• 攝護腺癌
• 肺癌
• 黑色素瘤
• 乳癌
• 結腸癌
• 其他

全球癌症疫苗市場規模：依最終用戶分類

• 醫院和診所
• 專業癌症治療中心
• 研究機構和學術機構
• 其他

全球癌症疫苗市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Merck & Co., Inc.
• GlaxoSmithKline plc
• Moderna, Inc.
• BioNTech SE
• F. Hoffmann-La Roche Ltd
• AstraZeneca PLC
• Sanofi SA
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• Astellas Pharma Inc.
• Daiichi Sankyo Company, Limited
• Novartis AG
• Dynavax Technologies Corporation
• OSE Immunotherapeutics SA
• Gritstone bio, Inc.
• PDS Biotechnology Corporation
• Sanpower Group
• Transgene SA

結論與建議

Global Cancer Vaccines Market size was valued at USD 12.0 Billion in 2024 and is poised to grow from USD 13.32 Billion in 2025 to USD 30.7 Billion by 2033, growing at a CAGR of 11.0% during the forecast period (2026-2033).

The global cancer vaccine market has transitioned from a niche sector to a focal point in healthcare, driven by immuno-oncology advancements and rising demand for effective vaccines. Cancer vaccines serve dual purposes: they can prevent oncogenic viruses and therapeutically prime the immune system against tumor-specific antigens, potentially reducing long-term care costs due to their enduring responses. The market has evolved from traditional prophylactic vaccines to novel autologous therapies and cutting-edge neoantigen and mRNA technologies. Technological innovations, including genomic sequencing and scalable mRNA production, are lowering barriers for development, attracting investment from both the private sector and major pharmaceutical companies for late-stage trials. Additionally, alignment with regulatory frameworks creates lucrative opportunities in adjuvant therapies, emergent markets, and strategic partnerships aimed at personalized vaccine solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Vaccines Market Segments Analysis

Global cancer vaccines market is segmented by vaccine type, technology, indication (cancer type), end-user and region. Based on vaccine type, the market is segmented into Preventive (Prophylactic) Cancer Vaccines, Therapeutic Cancer Vaccines and Combined Vaccines. Based on technology, the market is segmented into Recombinant Cancer Vaccines, mRNA & Neoantigen Personalized Vaccines, Viral Vector & DNA Vaccines, Whole-cell & Dendritic Cell Vaccines, Peptide-based Vaccines and Antigen/Adjuvant Cancer Vaccines. Based on indication (cancer type), the market is segmented into Cervical Cancer, Prostate Cancer, Lung Cancer, Melanoma, Breast Cancer, Colorectal Cancer and Others. Based on end-user, the market is segmented into Hospitals & Clinics, Specialty Cancer Treatment Centers, Research Institutes & Academic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Vaccines Market

The Global Cancer Vaccines market is significantly driven by advancements in antigen discovery, delivery systems, and adjuvant formulation, which have enhanced the efficacy and applicability of cancer vaccines across various tumor types. These innovations reduce scientific ambiguity, facilitate smoother translational processes, and elevate the therapeutic value perceived by clinicians and developers. This environment fosters increased investment, collaborative research efforts, and prioritization of cancer vaccine development within research pipelines. Consequently, the accelerated progression of candidates and the diversification of vaccine types contribute to market growth by enriching the overall product landscape and bolstering confidence among stakeholders in the industry.

Restraints in the Global Cancer Vaccines Market

The complexity of navigating stringent regulatory requirements and diverse approval frameworks across various regions poses a significant challenge for the development and market introduction of cancer vaccines. This multifaceted landscape heightens uncertainty and extends development timelines. The obligation to clearly demonstrate clinical benefits, adapt trial designs effectively, and meet distinct safety standards creates substantial evidentiary demands that can discourage smaller developers while hindering the advancement of their portfolios. The fragmentation of regulatory processes also amplifies the resources needed for compliance and strategic planning, subsequently slowing the progression of new vaccine candidates towards approval and restricting their market entry rates.

Market Trends of the Global Cancer Vaccines Market

The Global Cancer Vaccines market is witnessing a significant shift towards personalized neoantigen vaccines, reflecting the broader movement in precision oncology towards individualized treatments that align with unique patient tumor profiles. Developers are increasingly focusing on biomarker-driven patient selection and diagnostics to optimize therapeutic efficacy. Commercial strategies are being tailored to target specific patient populations, with an emphasis on value-based reimbursement models gaining traction among payers. Additionally, manufacturing and supply chain processes are evolving to adopt agile, on-demand workflows, while regulatory pathways and trial designs are being refined to support these personalized approaches, alongside a growing emphasis on real-world evidence to substantiate clinical benefits across a variety of tumor types.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Cancer Vaccines Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Preventive (Prophylactic) Cancer Vaccines
• Therapeutic Cancer Vaccines
• Combined Vaccines

Global Cancer Vaccines Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Recombinant Cancer Vaccines
• mRNA & Neoantigen Personalized Vaccines
• Viral Vector & DNA Vaccines
• Whole-cell & Dendritic Cell Vaccines
• Peptide-based Vaccines
• Antigen/Adjuvant Cancer Vaccines

Global Cancer Vaccines Market Size by Indication (Cancer Type) & CAGR (2026-2033)

• Market Overview
• Cervical Cancer
• Prostate Cancer
• Lung Cancer
• Melanoma
• Breast Cancer
• Colorectal Cancer
• Others

Global Cancer Vaccines Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Specialty Cancer Treatment Centers
• Research Institutes & Academic Centers
• Others

Global Cancer Vaccines Market Size & CAGR (2026-2033)

• North America (Vaccine Type, Technology, Indication (Cancer Type), End-User)
  • US
  • Canada
• Europe (Vaccine Type, Technology, Indication (Cancer Type), End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, Technology, Indication (Cancer Type), End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, Technology, Indication (Cancer Type), End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Technology, Indication (Cancer Type), End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OSE Immunotherapeutics SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gritstone bio, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PDS Biotechnology Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanpower Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transgene SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations